Glp-1 Receptor Pet Imaging Agent

positron emission tomography (PET) imaging.

Somatostatin receptor imaging Somatostatin is a regulatory peptide, widely expressed in the human body. SSTRs are present in normal human tissues, such as the thyroid, spleen, liver, kidneys and pituitary gland and the bladder by renal clearance.

As we can see from the illustration, Glp-1 Receptor Pet Imaging Agent has many fascinating aspects to explore.

The team used the imaging agent 21-18F fluorofuranylnorprogesterone (FFNP), created by co-author and University of Illinois chemist John Katzenellenbogen, Ph.D., Dehdashtis team assessed via PET scan the number of progesterone receptors there are on the surface of a cancer cell.

All currently available GLP-1 receptor agonists (GLP-1RAs) are, however, injectable. Ongoing efforts to advance this class of agents include, therefore, attempts to develop an oral formulation.18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma.

In 1 patient, GLP-1 receptor imaging was the only method that successfully localized the primary tumor in the pancreas. In 3 patients with sst(2)-expressing tumors, DOTATATE radiotherapy was effectively applied.

The recent introduction of PET imaging with gallium-68 has major bearings in current and future clinical practice. Its labelling with DOTA compounds has cleared the way for somatostatin receptor imaging with a viable PET agent...